Targeting Metabolic Reprogramming for the Prevention and Treatment of Proliferative Vitreoretinopathy

Abstract

This is our second year on the project, and we have published our findings identifying the key metabolic reprogramming traits associated with proliferative vitreoretinopathy (PVR) using our in-vitro model of epithelial-mesenchymal transition (EMT) of human retinal pigment epithelial cells (RPE). We have identified promising metabolic drugs which effectively block retinal EMT in vitro to be tested in our in vivo rabbit ocularsurgery model of PVR. Since re-opening of the lab, we have now collected a total of 34 human vitreous samples. We have sent through primary human RPE cells for metabolomics processing and will compare these results with our ARPE19 cell line data. We have identified another cytokine that induces EMT of RPE, namely, tumor necrosis factor-alpha, and found that it exerts opposite effects to metabolic reprogramming compared to transforming growth factor-beta and found a novel metabolic drug, dimethyl fumarate (DMFu) that blocks to activity of tumor necrosis factor-alpha.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1166352

Entities

People

  • Betty Diamond
  • Daisy Y Shu
  • Magali Saint-geniez

Organizations

  • Schepens Eye Research Institute

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biological Factors
  • Biological Pigments
  • Biomedical Research
  • Cells
  • Chemistry
  • Confocal Microscopy
  • Culture Techniques
  • Cytokines
  • Epithelial Cells
  • Eye Diseases
  • Gene Expression
  • Growth Factors
  • Medical Personnel
  • Metabolic Pathways
  • Metabolomics
  • Peptide Growth Factors
  • Peptides
  • Proteins
  • Retinal Diseases

Fields of Study

  • Biology
  • Medicine

Readers

  • Molecular and Cellular Biology
  • Oncology (Cancer Research).
  • Vision Science/Vision Psychology/Cognitive Neuroscience.